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The NLRP3 inflammasome is involved in caspase-1-
dependent maturation of IL-1b in many contexts. A
two-signal model has emerged for IL-1b maturation,
with LPS providing ‘‘signal I’’ and diverse agents
such as ATP, Nigericin, streptolysin O, uric acid crys-
tals, and alum salts capable of acting as ‘‘signal II.’’ In
the absence of signal II, pro-IL-1b is upregulated but
typically fails to be processed or released. What uni-
tes signal II stimuli has been debated, with the ability
to promote K+ efflux suggested as a common factor,
but the mechanism of IL-1b release remains unclear.
Here, we show that all examined inflammasome
signal II agents triggered necrosis, which was highly
correlated with their ability to promote IL-1b release.
IL-1b secretion occurred in tandem with the release
of many additional proteins and was confined to
necrotic cells. Thus, signal II agents initiate inflam-
mation by promoting necrosis-driven IL-1b release,
suggesting that IL-1b represents an inducible danger
signal.
INTRODUCTION
The NLRP3 inflammasome is a caspase-1-activating complex
that is involved in IL-1b processing and activation in response
to pathogens or sterile injury (Agostini et al., 2004; Mariathasan
et al., 2006; Franchi et al., 2012). This complex, which is
comprised of NLRP3, ASC, and caspase-1, is assembled in
response to bacterial lipopolysaccharide (LPS) and is activated
by diverse stimuli (Agostini et al., 2004; Mariathasan et al.,
2006). Most cell types are devoid of IL-1b and only synthesize
this in response to detection of LPS via TLR4. However, LPS
alone fails to induce robust processing and activation of IL-1b
in most cell types (Franchi et al., 2012), which has led to the
emergence of a two-signal model for IL-1b processing and
release.
In the two-signal model of inflammasome activation, ‘‘signal I’’
(LPS or another pathogen-associated molecular pattern) in-
duces the expression of pro-IL-1b as an inactive 32-kDa precur-
sor but fails to trigger maturation or release of this cytokine. ForCeproductive IL-1b processing and secretion, a second signal
(‘‘signal II’’) induces processing of pro- IL-1b to the p17 active
form, which is then released into the extracellular space. The
mechanism of IL-1b release has been much debated, with
some suggesting that caspase-1 is involved in the selective
transport of IL-1b across the plasma membrane (Brough and
Rothwell, 2007), whereas others suggest that membrane micro-
vesiculation is involved (MacKenzie et al., 2001). Yet another
putative mechanism involves ATP-mediated triggering of mem-
brane P2X7R channels, resulting in P2X7R-dependent formation
of multi-vesicular bodies containing inflammasome compo-
nents, with subsequent membrane fusion and release of
IL-1b-containing exosomes (Qu et al., 2007). However, a mech-
anism for IL-1b release that unites all signal II stimuli has yet to
emerge.
Somewhat perplexingly, a plethora of diverse agents have
been shown to be capable of acting as signal II for IL-1b process-
ing and secretion. These include the pore-forming toxins strep-
tolysin O (Harder et al., 2009), Nigericin (Franchi et al., 2012),
maitotoxin (Mariathasan et al., 2006), and valinomycin (Gurcel
et al., 2006), as well as the P2X7 channel activator ATP (Perre-
gaux et al., 1996), uric acid, and silica crystals (Martinon et al.,
2006; Dostert et al., 2008) and the widely used adjuvant
aluminum hydroxide (alum; Eisenbarth et al., 2008). Many of
these agents are capable of triggering K+ efflux from the cell,
and indeed, addition of excess K+ to the extracellular space sup-
presses activation of the NLRP3 inflammasome and IL-1b
release (Pe´trilli et al., 2007; Mun˜oz-Planillo et al., 2013). How-
ever, numerous additional agents have also been found to
induce processing and release of IL-1b, ranging from the cyto-
toxic drug daunorubicin, UV treatment, and histones (Feldmeyer
et al., 2007; Sauter et al., 2011; Allam et al., 2013). What all of
these agents share in common is unclear, and no unified mech-
anism of NLRP3-dependent IL-1b processing and release has
emerged.
One hypothesis is that extracellular ATP, released during
inflammation, might act as a common signal for the opening of
P2X7 membrane channels, thereby facilitating K+ release
(Sanz and Di Virgilio, 2000; Labasi et al., 2002). However,
P2X7-null cells are capable of activating the NLRP3 inflamma-
some and degradation of extracellular nucleotides did not
inhibit LPS-driven inflammation in vivo (Franchi et al., 2007; He
et al., 2013). In addition, concentrations of ATP that are required
to promote P2X7-dependent inflammasome activation inll Reports 11, 1535–1548, June 16, 2015 ª2015 The Authors 1535
experimental settings are typically in the non-physiological,
micromolar range and are unlikely to be achieved in vivo.
Furthermore, inflammasome activation by flagellin or intracel-
lular bacteria, as well as in vivo administration of LPS, proceeded
independently of the P2X7R (Franchi et al., 2007; He et al., 2013).
A caspase-activating complex similar to the NLRP3 inflamma-
some, the Apaf-1/caspase-9 apoptosome, is activated by
numerous divergent stimuli and promotes apoptosis-associated
caspase activation (Taylor et al., 2008; Adrain and Martin, 2009).
Whereas numerous cytotoxic stimuli activate the inflammasome,
all of these ultimately converge on mitochondria to trigger as-
sembly of the Bax/Bak channel and efflux of cytochrome c
from mitochondria. Within the cytosol, cytochrome c triggers
the assembly of the Apaf-1 apoptosome and is the only known
activator of this complex. Thus, whereas activators of the apop-
tosome are chemically and physically highly diverse, they all
ultimately utilize the samemechanism of activating this complex:
mitochondrial permeabilization. Thus, the Apaf-1 apoptosome
acts as a sensor for mitochondrial permeabilization by binding
to a molecule (cytochrome c) that is normally sequestered within
healthy mitochondria.
Given the precedent established by activation of the Apaf-1/
caspase-9 apoptosome, it is highly probable that the highly
diverse triggers of the NLRP3 inflammasome also converge on
some common event that is sensed by this complex. Here, we
demonstrate that all signal II stimuli examined led to non-selec-
tive permeabilization of plasmamembranes to promote necrosis
and IL-1b release. We also show that signal-II-initiated necrosis
and associated IL-1b maturation and release were all blocked
through raising extracellular K+. Taken together, these data
argue that agents capable of triggering plasma membrane dam-
age or permeabilization, leading to a decline in intracellular K+
levels and concurrent necrosis, can serve as signal II for
activation of the NLRP3 inflammasome. Thus, similar to the
apoptosome, which detects permeabilization of mitochondrial
membranes, the NLRP3 inflammasome detects permeabiliza-
tion of the plasma membrane and acts as a sensor for ‘‘danger’’
or ‘‘necrotic cell death’’.
RESULTS
LPSTreatmentUpregulates Pro-IL-1bbut Leads to Little
Processing or Release
As previously described in many studies, LPS stimulation of
THP-1 monocytic cells led to the production of multiple cyto-
kines and chemokines and robust upregulation of pro-IL-1b
but little processing or secretion of IL-1b into the extracellular
space (Figures 1A and 1B). However, addition of diverse agents,
such as Nigericin, ouabain, valinomycin, streptolysin O, ATP, or
LLOMe, which are all known to be capable of acting as signal II
stimuli for the NLRP3 inflammasome, led to robust IL-1b pro-
cessing and release of mature p17 IL-1b from the same cells
(Figures 1C and 1D). To demonstrate that the processed and
secreted p17 IL-1b was indeed active, we transferred THP-1
cell supernatants onto HeLa cells, which are IL-1 responsive
(but LPS insensitive) and generate robust amounts of IL-6 and
IL-8 in response to IL-1b (Afonina et al., 2011). All signal II agents
tested induced robust IL-1b activation and secretion from THP-11536 Cell Reports 11, 1535–1548, June 16, 2015 ª2015 The Authorscells, as assessed by IL-6 and IL-8 secretion in the HeLa cell
bioassay (Figure 1E). We confirmed that the latter cytokines
were generated by HeLa cells in an IL-1b-dependent manner
through use of specific neutralizing antibodies to the latter,
whereas neutralizing antibodies directed against IL-1a, IL-33,
or TNF failed to inhibit IL-6/IL-8 production in this context
(Figure 1F).
Signal II Stimuli Share in Common the Ability to Promote
Necrosis
What signal II agents have in common has been debated, but it is
clear that a drop in intracellular K+ is one of the common effects
of many of these agents (Mun˜oz-Planillo et al., 2013). The mech-
anism of IL-1b release also remains unresolved; however, we
considered the simple hypothesis that agents capable of acting
as signal II simply trigger necrosis, which is invariably preceded
by a drop in intracellular K+ as plasmamembrane permeability is
lost, which would lead to inflammasome activation followed
rapidly by IL-1b release as a consequence of the complete
loss of membrane integrity.
This hypothesis makes three predictions: first, that the ability
of signal II agents to promote IL-1b processing and release is
closely correlated with their ability to promote necrosis; second,
that IL-1b release is non-selective and accompanied by
numerous additional cytosolic proteins; and third, that IL-1b
release only occurs from necrotic, but not viable, cells. To
explore whether necrosis is the common mechanism of inflam-
masome-dependent IL-1b secretion, we initially asked whether
signal II stimuli induced necrosis within the ranges that they
exhibit activity as initiators of IL-1b maturation and release. As
Figures 2A and 2B demonstrate, all signal II stimuli tested
induced cell death in a dose-dependent manner, which was
highly correlated with their ability to trigger mature IL-1b release,
as measured by the HeLa bioassay. Of note, signal II agents pro-
moted cell death irrespective of whether cells were treated with
LPS or not (Figure S1), suggesting that the cell death seen in this
context was independent of inflammasome activation. In further
support of this, the poly-caspase inhibitor zVAD-fmk failed to
block LPS+signal II-driven cell death but completely inhibited
LPS+signal II-initiated IL-1b production, as indicated by the
HeLa bioassay (Figure S1). Furthermore, knockdown of the
inflammasome constituents NLRP3, ASC, or caspase-1 (Fig-
ure S2A) failed to attenuate signal II-associated cell death (Fig-
ures S2B and S2D–S2F) but profoundly attenuated IL-1b
processing (Figure S2C) and the release of bioactive IL-1b (Fig-
ures S2B and S2D–S2F). Collectively, these data suggest that
signal II agents are intrinsically cytotoxic and induce cell death
independent of LPS or inflammasome activation.
Signal-II-Induced Cell Death Occurs via Conventional
Necrosis
The morphology of cell death observed in response to signal II
agents appeared to be necrotic, rather than apoptotic, as cells
underwent high-amplitude swelling and ballooning, followed by
rapid membrane permeabilization in response to signal II stimuli
(Figure 2C). Moreover, cells treated with the latter agents failed
to display nuclear hypercondensation or fragmentation typical
of apoptosis and underwent simultaneous uptake of the vital
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Figure 1. Diverse Signal II Agents Promote IL-1b Processing and Release
(A) THP-1 cells were primed with LPS (1 mg/ml) for the indicated durations. Cell lysates and clarified culture supernatants were analyzed bywestern blotting for the
indicated proteins.
(B) THP-1 cells from (A) were scored for necrosis by PI staining by flow cytometry, and cytokine concentrations in the culture supernatants were measured by
ELISA.
(C) THP-1 cells were primed with LPS (1 mg/ml) for 4 hr and then treated with Nigericin (2.5 mM), ouabain (5 mM), valinomycin (400 mM), SLO (1.0 mg/ml), ATP
(30 mM), or LLOMe (0.5 mM). After 6 hr, cell lysates and culture supernatants were analyzed by western blotting for the indicated proteins.
(D) Cells from (C) were scored for necrosis by PI staining by flow cytometry, and IL-1b concentrations in the culture supernatants were measured by ELISA.
(E) THP-1 culture supernatants from (C) were diluted 1:100 in culture medium and added to HeLa cells, which express IL-1R, to measure active IL-1. After 24 hr,
IL-6 and IL-8 concentrations in the HeLa culture supernatants were measured by ELISA.
(F) To determine the contribution of IL-1b to HeLa bioactivity, Nigericin and ouabain THP-1 culture supernatants from (E) were immunodepleted for the indicated
cytokines and added to HeLa cells. After 24 hr, IL-6 concentrations in the culture supernatants were measured by ELISA. Results shown are representative of
least two independent experiments.
Error bars represent the mean ± SEM of triplicate determinations from a representative experiment. See also Figure S1.dye propidium iodide in tandem with annexin V binding, charac-
teristic of necrosis (Figure 2C). Furthermore, signal II agents
failed to activate apoptotic caspases (caspases-3/-7) or process
caspase substrates that are typically cleaved during apoptosis
(Figure 2D). In addition, knockdown of the ‘‘apoptotic’’ cas-Cepases, caspase-3 and caspase-7, failed to attenuate cell death
in response to signal II but did so in response to actinomycin
D, a conventional pro-apoptotic stimulus (Figure 2E). Collec-
tively, these data suggest that necrosis could be a common
mechanism for IL-1b release induced by signal II stimuli.ll Reports 11, 1535–1548, June 16, 2015 ª2015 The Authors 1537
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Figure 2. Signal II Stimuli Are Cytotoxic and Promote Necrosis
(A) THP-1 cells were primed with LPS (1 mg/ml) for 4 hr and then treated with the indicated signal II agents. Six hours later, necrosis was scored by PI staining by
flow cytometry and clarified supernatants were added to HeLa cells at a 1:100 dilution. Twenty-four hours later, IL-6 concentrations in the HeLa culture su-
pernatants were measured by ELISA.
(B) Flow cytometry analysis from (A).
(legend continued on next page)
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Because certain forms of necrosis occur in a programmed
manner, called necroptosis, we also asked whether the necrop-
tosis inhibitor necrostatin-1 had any inhibitory effect on LPS+sig-
nal II-induced necrosis. However, as shown in Figures S3A and
S3B, necrostatin-1 failed to attenuate LPS+signal II-induced
necroptosis but did block TNF/zVAD-induced necroptosis in
HeLa cells stably overexpressing RIPK3, as expected. Similarly,
knockdown of the necroptosis regulatory molecules RIPK1,
RIPK3, or MLKL also failed to block LPS+signal II-induced ne-
crosis (Figures S3C–S3F), but this was effective in arresting
TNF/zVAD-induced necroptosis, as expected. Thus, signal II
agents appear to induce conventional necrosis rather than
necroptosis.
The Degree of Necrosis Induced by Signal II Stimuli Is
Highly Correlated with Their Ability to Promote IL-1b
Maturation and Release
We next explored whether the ability of signal II agents to pro-
mote necrosis correlated with their ability to promote IL-1b pro-
cessing, IL-1b release into the cell supernatant, as well as the
generation of IL-1b bioactivity. As Figure 3A demonstrates, we
observed a very close correlation between the degree of necro-
sis observed at a given dose of Nigericin and the extent of IL-1b
processing, IL-1b secretion, and the appearance of IL-1b bioac-
tivity in the culture supernatants. Of particular note, we also
observed release of multiple additional irrelevant proteins
(XIAP, p23, Bax, vimentin, b-catenin, and actin) into the cell su-
pernatants in concert with mature p17 IL-1b, which strongly sug-
gests that release of this cytokine is unselective (Figure 3A).
Indeed, where p17 IL-1b release was detected, we also
observed release of pro-IL-1b in tandem (Figure 3A). Essentially
identical results were observed with three other signal II agents
(ouabain, valinomycin, and SLO) tested (Figures 3B–3D). Thus,
IL-1b release mirrors the ability of signal II agents to promote
cell death.
TheOnset of IL-1bReleaseCorrelates Preciselywith the
Onset of Necrosis
To explore further whether inflammasome-dependent IL-1b
releasewas due to necrosis, we conducted time course analyses
at closely spaced time intervals to determine whether the onset
of IL-1b processing and release was coincident with the appear-
ance of necrotic cells in these cultures. As shown in Figures 4A
and 4B, the appearance of IL-1b bioactivity, as well as the
release of processed p17 IL-1b, in THP-1 cell supernatants
was highly correlated with the onset of necrosis induced by Ni-
gericin and ouabain. We also made very similar observations
with valinomycin (Figure S4A). Furthermore, similar observations
were alsomade using themurinemacrophage cell line J774 (Fig-
ures S4B and S4C). Once again, we also observed the release of(C) THP-1 cells treated with PMA (250 nM) and then plated on glass slides. Sixtee
(2.5 mM). Cells were analyzed by phase contrast microscopy and then stained
Alternatively, cytospins were generated and stained for hematoxylin and eosin, f
(D and E) THP-1 cells were transfectedwith either nonsilencing siRNA or siRNAs d
cells were primed with LPS (1 mg/ml) for 4 hr and then treated with Nigericin (2.5 mM
necrosis by PI staining by flow cytometry, whereas cell lysates were analyzed by
least two independent experiments.
Error bars represent the mean ± SEM of triplicate determinations from a represe
Cemultiple additional cytosolic proteins into the cell supernatants in
tandem with IL-1b (Figures 4A, 4B, and S4A–S4C), consistent
with a non-selective release mechanism. These data argue that
signal II agents promote necrosis, which acts as a driver of
IL-1b secretion simply as a consequence of plasma membrane
rupture.
IL-1b Processing Occurs Intracellularly
The observation that both pro- and mature IL-1b could be de-
tected in the cell supernatants (Figures 3 and 4) presented the
possibility that IL-1b maturation could occur extracellularly. To
explore this possibility, we used two different strategies. First,
we added recombinant full-length pro-IL-1b to the cell culture
medium of cells treated with LPS/Nigericin or LPS/SLO to ask
whether processing of extracellular His-tagged IL-1b occurred
under conditions where endogenous IL-1b was processed and
released. However, we failed to detect processing of extracel-
lular His-tagged IL-1b, above background levels, under condi-
tions where cell-associated IL-1b underwent processing and
release (Figures S5A and S5B). In contrast, recombinant cas-
pase-1 readily processed recombinant His-tagged IL-1b,
demonstrating that it was not incapable of undergoing proteo-
lytic maturation (Figures S5A and S5B). Second, we also added
the caspase-1-inhibitory serpin PI-9 to the cell culture medium to
determine whether this could inhibit LPS+signal II-induced IL-1b
processing (Figures S5C–S5E). As Figure S5E shows, PI-9 failed
to inhibit LPS+Nigericin or LPS+SLO-mediated IL-1b processing
when added to cell culture, whereas PI-9 readily inhibited recom-
binant caspase-1-mediated IL-1b processing in control reac-
tions (Figure S5D).
Collectively, these data suggest that, although pro- and
mature IL-1b are released in tandem, IL-1b processing does
not occur in the extracellular space to any significant degree.
Viable Cells Retain IL-1b after Exposure to Signal II
Agents
Although the onset as well as the magnitude of necrosis
observed in the preceding experiments correlated very well
with the onset and magnitude of IL-1b release, it was formally
possible that viable, non-necrotic, cells could contribute to the
IL-1b release seen in mixed (i.e., viable and necrotic) cell popu-
lations. To rule out this possibility, we also explored inflamma-
some-dependent IL-1b release using several additional
approaches. In the first, we used flow cytometry to stain for intra-
cellular IL-1b versus forward scatter, which correlates very well
with loss of plasma membrane permeability (Figures 2B and
5A, left hand column). As Figure 5A demonstrates, LPS treat-
ment alone dramatically increased intracellular IL-1b staining,
as expected. However, when THP-1 cells were stimulated with
LPS in combination with ouabain to promote IL-1b maturationn hours later, cells were treated for 8 hr with Nigericin (2.5 mM) or actinomycin D
with either annexin V-FITC, PI, or Hoescht and analyzed by UV microscopy.
ollowed by analysis by microscopy.
irected against caspase-1 or caspase-3/-7 as indicated. Forty-eight hours later,
) or actinomycin D (2.5 mM). At the indicated time points, cells were scored for
western blotting for the indicated proteins. Results shown are representative of
ntative experiment. See also Figure S2.
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Figure 3. Signal-II-Induced IL-1b Release Is Unselective and Closely Correlated with Necrosis
(A–D) THP-1 cells were primed with LPS (1 mg/ml) for 4 hr and then treated with the indicated doses of Nigericin (A), ouabain (B), valinomycin (C), and
SLO (D). Six hours later, cells were analyzed by phase contrast microscopy and scored for necrosis by PI staining by flow cytometry, whereas cell
(legend continued on next page)
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and release, we observed a dramatic reduction in forward scat-
ter (which occurs as a consequence of membrane permeabiliza-
tion) and these cells stained markedly less intensely for IL-1b
than their viable counterparts (Figure 5A). Furthermore, we also
stained for a number of additional intracellular proteins under
the same conditions and observed similar non-selective release
of p62, Bax, cytochrome c, and actin under conditions where
IL-1b was released (Figure 5A). In all cases, cells that stained
negative for the latter proteins exhibited low forward scatter
characteristics, indicative of necrosis.
In the second approach, we plated cells on coverslips fol-
lowed by treatment with PMA to promote adherence as well as
pro-IL-1b production. Cells were treated with PMA alone or in
combination with Nigericin followed by staining withMitotracker,
which is only taken up by viable cells that contain polarized mito-
chondria. Cells were then fixed and permeabilized to stain for
intracellular IL-1b. As Figure 5B demonstrates, only Mito-
tracker-positive cells were positive for intracellular IL-1b,
whereas neighboring Mitotracker-negative cells were essentially
devoid of IL-1b. Once again, these data argue that necrotic cells
are responsible for the majority of IL-1b secretion in response to
signal II agents.
In the third approach, we used quantitative ELISA assays to
measure the precise amount of intracellular IL-1b available for
release (i.e., cell-associated) versus the amount actually
released (i.e., supernatant-associated) in response to LPS+Ni-
gericin or LPS+ouabain and asked whether this correlated with
the percentage of cell death observed in response to these treat-
ments. As Figures 5C and 5D demonstrate, cell viability and
IL-1b retention, or conversely cell death and IL-1b release into
the medium, were very highly correlated.
Single Cell Analysis Reveals that Only Necrotic Cells
Release IL-1b
As an additional approach to explore the mechanism of IL-1b
release in response to signal II agents, we used confocal micro-
scopy in tandem with a novel strategy to detect IL-1b secretion
from cells in situ. Here, we coated coverslips with anti-IL-1b cap-
ture antibodies, followed by plating of live cells onto the capture
antibody-coated coverslips. Adherent cells were then treated
with LPS in the presence or absence of signal II agents. Prior
to termination of the experiments, we added a FITC-tagged sec-
ondary antibody to the cultures to detect secreted IL-1b that was
captured by the slide-immobilized antibodies. Furthermore, cul-
tures were also incubated with Mitotracker, which is only incor-
porated into live cells. Following this, cells were then washed to
remove excess unbound anti-IL-1b antibodies and were fixed.
Using this approach, only extracellular IL-1b is detected as
neither the capture or detection anti-IL-1b antibodies can pene-
trate viable cells.
In this scenario, if viable cells released IL-1b, this would be ex-
pected to lead to a halo of IL-1b reactivity (i.e., green/FITC)
surrounding Mitotracker-positive (i.e., red) cells. However, iflysates and culture supernatants were analyzed by western blotting for the
cells at a 1:100 dilution. Twenty-four hours later, IL-6 concentrations in the
representative of least two independent experiments. Error bars represent t
iment. See also Figure S3.
Cenecrotic (dead) cells were the only cells to release IL-1b, then
all cells with IL-1b ‘‘halos’’ would be expected to be Mitotracker
negative. As illustrated in Figure 6, all of the cells where IL-1b ha-
los were detected were essentially Mitotracker negative. Indeed,
we failed to detect any extracellular IL-1b halos surrounding
Mitotracker-positive cells. Once again, these data argue that ne-
crosis is the primary driver of IL-1b release in response to signal II
agents.
Known Inhibitors of IL-1b Release Block Cell Death
Collectively, the preceding results suggested that cell death
was necessary for IL-1b release in response to signal II agents.
We therefore wondered whether agents known to block IL-1b
release did so by blocking cell death. We addressed this ques-
tion using two different approaches. Elevated extracellular K+
is well known to block inflammasome activation and IL-1b
release (Perregaux and Gabel, 1994; Pe´trilli et al., 2007). If
cell death is the primary route of IL-1b release, our model
would predict that elevations in extracellular K+ would block
IL-1b release by suppressing cell death induced by signal II
agents. To test whether this was indeed the case, we treated
LPS-primed THP-1 cells with Nigericin in the presence of range
of KCl concentrations. Elevated extracellular K+ efficiently
blocked maturation and release of mature IL-1b, as expected
(Figures 7A and 7C). However, in agreement with the idea
that IL-1b release occurs via necrosis, K+ also blocked cell
death associated with Nigericin treatment (Figure 7A). This ef-
fect was observed at K+ concentrations ranging from 10 to
40 mM, with the degree of suppression of IL-1b release corre-
lating very well with suppression of cell death (Figures 7A and
7C). We also made similar observations with SLO (Figures 7B
and 7C) as well as ouabain (data not shown), where the sup-
pression of IL-1b release also occurred in tandem with sup-
pression of cell death.
The type 2 diabetes drug glyburide has also been shown to
block IL-1b release, through an unknown mechanism (Lamkanfi
et al., 2009). As shown in Figures 7D–7F, glyburide-mediated in-
hibition of IL-1b releasewas also associated with inhibition of cell
death associated with signal II treatment. Thus, two well-known
inhibitors of IL-1b secretion also blocked cell death associated
with signal II agents, which strongly supports the idea that necro-
sis is the major route of IL-1b release.
Where Signal II Is Not Required, Signal I Is Sufficient
to Promote Necrosis
Certain cell types, such as bone-marrow-derived macrophages
(BMDMs), do not require signal II agents to promote IL-1b
release, and in these cells, LPS treatment alone is sufficient (Fig-
ure 7G). The necrosis-release model would predict that, in such
cells, LPS treatment alone should induce cell death, which is why
signal II is not required. Therefore, we asked whether this was
indeed the case. As Figures 7H and 7I demonstrate, LPS was
sufficient to promote necrosis of primary BMDMs, with theindicated proteins. In addition, clarified supernatants were added to HeLa
HeLa culture supernatants were measured by ELISA. Results shown are
he mean ± SEM of triplicate determinations from a representative exper-
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Figure 4. IL-1b Release Is Coincident with the Onset of Necrosis
(A and B) THP-1 cells were primed with LPS (1 mg/ml) for 4 hr and then treated with Nigericin (5 mM) (A) or ouabain (20 mM) (B) and samples taken at the indicated
time points. Cells were scored for necrosis by PI staining by flow cytometry, whereas cell lysates and culture supernatants were analyzed by western blotting
for the indicated proteins. In addition, clarified supernatants were added to HeLa cells at a 1:100 dilution. Twenty-four hours later, IL-6 and IL-8 concentrations
in the HeLa culture supernatants were measured by ELISA. Results shown are representative of least two independent experiments. Error bars represent the
mean ± SEM of triplicate determinations from a representative experiment. See also Figure S4.
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degree of necrosis observed once again correlating very well
with the release of mature IL-1b seen.
Collectively, these results demonstrate that diverse signal II
agents promote LPS-initiated IL-1b maturation and release as
a consequence of their ability to trigger membrane permeabiliza-
tion and necrosis.
DISCUSSION
Here, we have shown that diverse signal II agents, including
Nigericin, ouabain, valinomycin, streptolysin O, ATP, and
LLOMe, share in common the ability to promote secretion of
bioactive mature IL-1b by inducing necrosis. Signal-II-induced
IL-1b release was non-selective, as this was accompanied by
the release of numerous intracellular proteins, including XIAP,
p23, Bax, and vimentin. Single cell analysis also revealed that
the only cells to release IL-1b in response to signal II agents
were those that underwent necrosis. These data suggest that
IL-1b behaves as an inducible ‘‘danger-associated molecular
pattern’’ (DAMP), with release of the latter cytokine contingent
upon the presence of a cytotoxic stimulus such as a bacterial
virulence factor.
The mechanism of IL-1b release has been debated, and
although cell lysis has commonly been reported in studies that
have sought to define the mode of IL-1b release, it is typically
argued that cytokine release precedes death. However, such
claims have been based primarily on insensitive cell death
assays such as GAPDH release. Here, using more-sensitive
assays, such as single cell analysis, we have shown that signal-
II-induced cell death and IL-1b release are highly correlated.
Moreover, agents that block IL-1b release, such as elevated
extracellular K+ as well as glyburide, also blocked cell death.
Whereas in this study we have focused on the NLRP3 inflam-
masome that is activated by LPS, it is interesting to note that
caspase-1 activation and IL-1b release in the context of other in-
flammasomes are well known to be associated with cell death.
Cytosolic bacterial flagellin activates the NAIP5/NLRC4 inflam-
masome, promoting caspase-1 activation and IL-1b processing
(Zhao et al., 2011). Interestingly, flagellin also promotes lysis of
infected cells, through caspase-dependent and independent
mechanisms (Miao et al., 2010; Lage et al., 2013). Similarly, the
AIM2 inflammasome responds to intracellular DNA detection
by instigating caspase-dependent IL-1b processing and pyrop-
tosis (Rathinam et al., 2010; Wu et al., 2010) as does the
NLRP1 inflammasome in response to anthrax lethal toxin (Mas-
ters et al., 2012). In light of our findings, it will be interesting to
determine the role of cell lysis as a facilitator of mature IL-1b
release in response to activation of other inflammasomes.
Whereas a unifying trigger for inflammasome activation has
yet to be firmly established, much evidence now strongly sug-
gests that a decline in intracellular K+ ions is a pre-requisite (Per-
regaux and Gabel, 1994; Walev et al., 1995; Pe´trilli et al., 2007,
Mun˜oz-Planillo et al., 2013). In this regard, it is possible that initial
signal II-mediated membrane permeabilization, without overt
cell lysis, may facilitate sufficient potassium efflux to promote in-
flammasome activation and IL-1b maturation. Signal-II-medi-
ated membrane permeabilization may then overwhelm the cell,
leading to necrosis and mature IL-1b release. In this scenario,Cesignal-II-mediated membrane permeabilization is responsible
for the intracellular K+ drop, which leads to activation of the in-
flammasome and also for the downstream release of IL-1b
through eventual cell lysis. Importantly, this scenario does not
preclude the possibility that activation of the inflammatory cas-
pases contribute, at least in part, to the membrane rupture that
eventually leads to IL-1b release. Thus, the K+ efflux that occurs
in response to diverse signal II agents may trigger two closely
related events: activation of the inflammasome followed by
plasma membrane rupture, which may well be facilitated by
the actions of active inflammatory caspases. However, we
have failed to find evidence for involvement of the inflammasome
in signal-II-induced cell death, either through blocking caspase
activity or knockdown of inflammasome constituents. This sug-
gests that signal II agents are intrinsically cytotoxic, without
recourse to the participation of the inflammasome in this
process.
The observation that necrosis is the common event that pro-
motes IL-1b release fits well with Matzinger’s ‘‘danger model,’’
which argues that cell death (danger) rather than detection of
‘‘non-self’’ is a key factor in the decision to initiate an immune
response (Matzinger, 1994). Non-self entities (such as LPS)
may serve only to prime responding cells, whereas the defining
event in the initiation of inflammation may be the detection of a
second, membrane-damaging signal that drives the K+ drop
necessary for activation of the inflammasome and release of
IL-1b and other DAMPs (also called alarmins). In this light,
IL-1b serves as an inducible DAMP that is generated as a conse-
quence of PAMP detection. Because a common feature of path-
ogenic organisms is to cause cell death within the host, this two-
step model incorporating tissue damage explains many of the
ambiguities in immunity, such as why PAMPs only typically
induce robust immunity when co-administered with noxious, tis-
sue-damaging adjuvants (Matzinger 1994), unless the PAMP it-
self is directly cytotoxic.
In conclusion, here we have shown that signal II agents share
in common the ability to promote cell lysis, which closely corre-
lated with their ability to facilitate inflammasome activation and
mature IL-1b release. Importantly, signal-II-induced IL-1b
release was unselective and was confined to necrotic cells.
Thus, cell-rupture-associated IL-1b release, downstream of
PAMP detection, may permit the immune system to discriminate
between pathogenic (i.e., cell-death-inducing) and non-patho-
genic micro-organisms, thereby qualifying the decision to
respond on the basis of whether a PAMP is detected in the
context of danger (i.e., necrotic cell death) or not.EXPERIMENTAL PROCEDURES
Reagents
Antibodies specific to caspase-3, caspase-7, RhoGDI, XIAP, gelsolin, RIPK1,
and p65 were obtained from BD Biosciences. Anti-CD2-AP, anti-human
caspase-1, and mouse caspase-1 (p20) antibodies were from Santa Cruz
Biotechnology, whereas mouse anti-caspase-1 was from Adipogen. Anti-IL-
1b antibody was from R&D Systems, whereas anti-co-chaperone p23
antibody was purchased from Affinity Bioreagents. Anti-human ASC, cas-
pase-4, and caspase-5 (M060-3, which also detects caspase-4) were from
MBL International. Anti-ERK antibody was from Cell Signaling Technology.
Mitotracker CMXROS was from Invitrogen. Nigericin was from Enzo Lifell Reports 11, 1535–1548, June 16, 2015 ª2015 The Authors 1543
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Figure 5. Viable Cells Retain IL-1b after Exposure to Signal II Agents
(A) THP-1 cells were left untreated or primed with LPS (1 mg/ml) for 20 hr and then treated with ouabain (1.25 mM). Four hours later, necrosis was measured by PI
staining by flow cytometry (top panel) and the cells were fixed with paraformaldehyde and permeabilized with Triton X-100 and then immunostained for intra-
cellular IL-1b, p62, Bax, cytochrome c, or actin and analyzed by flow cytometry. The percentage of live (high-FSC) or dead (low-FSC) THP-1 cells that released IL-
1b is shown (bottom panel).
(B) THP-1 cells were plated on glass slides in medium containing PMA (250 nM) to encourage cells to stick to the slides and to prime pro-IL-1b production.
Twenty hours later, the monolayer was washed in RPMI and RPMI containing Nigericin (1.25 mM) was added. Three hours later, Mitotracker CMX-ROS (25 nM)
(legend continued on next page)
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AB
Figure 6. Single Cell Analysis Reveals that
Only Necrotic Cells Release IL-1b
(A) Glass slides were coated with IL-1b capture
antibody. Twenty-four hours later, slides were
washed and THP-1 cells were plated in medium
containing PMA (250 nM) to encourage cells to
stick to the slides and to prime pro-IL-1b produc-
tion. Twenty hours later, the monolayer was
washed in RPMI and RPMI containing Nigericin
(1.25 mM) was added to promote the release of IL-
1b, which would subsequently be captured on the
slide-bound antibody surrounding the cells. At the
indicated time points, cells were washed gently in
PBS, 1% BSA, and slide-bound IL-1b was de-
tected by addition of streptavidin-FITC-conju-
gated IL-1b secondary antibody, whichwas added
in PBS, 1% BSA. Twenty minutes later, cells were
washed again and Mitotracker CMX-ROS (25 nM)
was added for 15min to stain exclusively for viable
cells. Finally, cells were washed gently in PBS and
then fixed and the nuclei stained with Hoescht,
followed by visualization of IL-1b release by UV-
confocal microscopy. The percentage of live (Mi-
totracker-positive) or dead (Mitotracker-negative)
THP-1 cells that released IL-1b is shown.
(B) Cells were treated as in (A), except that Niger-
icin (1.25 mM) or ouabain (10 mM) were added for
3 hr. Results shown are representative of least two
independent experiments.
Error bars represent the mean ± SEM of triplicate
determinations from a representative experiment.Sciences, and streptolysin O was from Aalto Bioreagents. Unless otherwise
indicated, all other reagents were purchased from Sigma.
Measurement of Cytokines and Chemokines
Cytokines and chemokines were measured from cell culture supernatants us-
ing specific ELISA kits obtained from R&D Systems (human and mouse IL-1b,
human and mouse IL-6, and human IL-8). Each assay was repeated a mini-
mum of three times, and all cytokine assays were carried out using triplicate
samples from each culture.was added for 15 min to stain exclusively for viable cells. Cells were then fixed and permeabilized as in (A
followed by staining of nuclei with Hoescht and analysis by UV confocal microscopy. The percentage of live (M
indicated by circles) THP-1 cells that released IL-1b is shown (side panel).
(C and D) THP-1 cells were primed with LPS (1 mg/ml) for 4 hr and then treated with the indicated doses of Nig
was measured by PI staining by flow cytometry, and the clarified supernatants were added to HeLa cells at a
HeLa supernatants by ELISA after a further 24 hr. At the 4-hr time point, THP-1 cells were also permeabilized
versus supernatants was determined by ELISA.
Results shown are representative of least two independent experiments. Error bars represent the mean ± SEM
experiment. See also Figure S5.
Cell Reports 11, 1535–154Treatment of THP-1 and J774 Cells with
Signal II Agents and HeLa Bioassay
THP-1 or J774 cells were primed with LPS
(1 mg/ml) for 4 hr and then treated with signal II
agents for 2–6 hr. A sample of cells was then taken
for necrosis measurement by PI staining by flow
cytometry and the remaining cells separated
from the medium by centrifugation at 600 g for
10 min, followed by lysing in SDS-PAGE sample
buffer. The medium was further clarified at 7,000
g for 5 min, which was important to make sure all
cells were removed, which would otherwise leadto false positives. 1:100 dilutions of THP-1 supernatant were then added to
HeLa cells and incubated overnight at 37C. After 24 hr, IL-6 and IL-8 concen-
trations in the HeLa culture supernatants were measured by ELISA. To deter-
mine the contribution of IL-1b to HeLa bioactivity, Nigericin and ouabain THP-1
culture supernatants were immunodepleted using antibodies directed against
IL-1b, IL-1a, TNFa, or IL-33 (1 mg/ml; 2 hr), which had been pre-coupled to A/G
agarose (20 ml). Two hours later, the agarose/antibody/protein complexes
were removed by centrifugation and the depleted supernatants added to the
HeLa bioassay. Alternatively, bioactive mouse IL-1b was measured directly) and immunostained for intracellular IL-1b or p62,
itotracker-positive) or dead (Mitotracker-negative,
ericin (C) or ouabain (D). Four hours later, necrosis
1:100 dilution followed by IL-6 measurement in the
with Trition-X100, and IL-1b concentration in cells
of triplicate determinations from a representative
8, June 16, 2015 ª2015 The Authors 1545
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(legend on next page)
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by ELISA. For experiments utilizing caspase or necroptosome inhibition,
zVAD-fmk (10 mM) or Necrostatin-1 (5 mM) was added to LPS-primed THP-1
for 1 hr before addition of signal II agents as described above.
Quantitative ELISA for Comparison of Cell- and Medium-Associated
IL-1b
THP-1 cells were primedwith LPS (1 mg/ml) for 4 hr and then treatedwith signal
II agents for 3–6 hr. A cell sample was then taken for necrosis measurement by
PI staining by flow cytometry and the remaining cells separated from the me-
dium by centrifugation at 600 g for 10 min, whereas the medium was further
clarified at 5,000 g for 5 min. Cell pellets were lysed in buffer containing 1%
TX-100 for 15 min. Lysates were then clarified by centrifugation at 20,000 g
for 15 min. IL-1b levels in cell lysates and supernatants were determined by
ELISA. Additionally, a HeLa bioassay was performed with the clarified
supernatants.
RNAi
To ablate protein expression in THP-1 or HeLa cells, 53 105 cells were trans-
fectedwith 200–400 nM siRNA using nucleofection (Amaxa; Program T-001 for
THP-1; I-19 for HeLa) as per manufacturer’s instructions. siRNA were as fol-
lows: NLRP3 no. 1: sense: 50-gguguuggaauuagacaac-30; NLRP3 no. 2: sense:
50-aagcuucagguguuggaauua-30; ASC no. 1: sense: 50-gaugcggaagcucuuca
gu-30; ASC no. 2: sense: 50-aagagcuuccgcaucuugcuugggu-30; caspase-1
no. 1: sense: 50-gguucgauuuucauuugag-30; caspase-1 no. 2: sense: 50-gguucg
auuuucauuugag-30; caspase-4 no. 1: sense: 50-guguagauguagaaga-30; cas-
pase-4 no. 2: sense: 50-aaguggccucuucacagucau-30; caspase-5 no. 1: sense:
50-gcuccaucuucauuacgga-30; caspase-5 no. 2: sense: 50-gcacucaucucuucac
agu-30; MLKL no. 1: sense: 50-gagauccaguucaacgaua-30; MLKL no. 2: sense:
50-ggaauaccguuucagaugu-30; RIPK3 no. 1: sense: 50-cccgacgaugucuucuguc
aa-30; RIPK3 no. 2: sense: 50-aagauuaaccauagccuucaccuccca-30; caspase-
3: sense: 50-ggaauaucccuggacaaca-30; and caspase-7: sense: 50-ccacgguuc
caggcuauua-30.
Intracellular Cytokine Staining
THP-1 cells were treated with PMA (250 nM) and plated overnight on cover-
slips. Cells were then incubated in RPMI for 2 hr to encourage attachment to
the slides and then treated with PMA (250 nM) and ouabain (1.25 mM) or Niger-
icin (2 mM) for 1–5 hr. Mitotracker CMX-ROS (200 mM) was then used to stain
live cells, and the monolayer was washed and cells were fixed in 2.7% para-
formaldehyde and permeabilized in 0.15% Triton X-100 in PBS (pH 7.2). Cells
were incubated in 2% BSA (Roche) for 30 min and antibodies against IL-1b or
p62 were added at 2.5–5 mg/ml for 1 hr followed by PBS washing and addition
of fluorescently conjugated secondary antibodies. Final washings included in-
cubation with 20 mM Hoechst (Sigma) for 10 min. Cells were mounted with
Slow Fade (Molecular Probes) and observed on a laser scanning microscope
(Olympus FV1000) using a 488-nm argon laser (green fluorescence), a 543-nm
HeNe laser (Mitotracker), and a 405-nm LD laser (Hoechst). Confocal images
were acquired with Fluoview 1000 V.1 application software, and images
were processed with Indesign (Adobe). For analysis by FACS, THP-1
cells were treated overnight with LPS (1 mg/ml) and then treated with ouabain
(5 mM) for 3 hr. Mitotracker CMX-ROS (200 mM) was then used to stain live
cells, and cells were washed once in PBS and then fixed, permeabilized,Figure 7. Elevated Extracellular K+ and Glyburide Inhibit IL-1b Release
(A–C) THP-1 cells were primed with LPS (1 mg/ml). Four hours later, cells were eit
Nigericin (5 mM; A) or SLO (1 mg/ml; B) was then added and the cells incubated fo
clarified THP-1 supernatants were added to HeLa cells at a 1:100 dilution followe
(A and B). In addition, culture supernatants were analyzed by western blotting fo
(D–F) THP-1 cells were primedwith LPS (1 mg/ml). Four hours later, cells were eithe
Nigericin (5 mM; D) or SLO (1 mg/ml; E), was then added and the cells incubated
(G) Mouse bone-marrow-derived macrophages (BMDM) were treated with the in
supernatants were measured by ELISA.
(H) Cells from (G) were scored for necrosis by PI staining by flow cytometry and
(I) BMDMs were treated with LPS (2 mg/ml) and then necrosis was measured by P
measured by ELISA. Results shown are representative of least two independent
Error bars represent the mean ± SEM of triplicate determinations from a represe
Ceand stained with antibodies directed toward IL-1b, p62, Bax, cytochrome c,
or Actin, followed by PBS washing and addition of fluorescently conjugated
secondary antibodies. Cells were then analyzed by flow cytometry.
Assessment of Extracellular IL-1b Proteolysis
THP-1 cells (23 106/ml) were primed with LPS (1 mg/ml) for 4 hr and then cells
were aliquoted to two equal fractions, one of which was doped with recombi-
nant His-tagged pro-IL-1b (1 ng/ml). Cells were treated with signal II agents
and then 8 hr later cell death was determined by PI staining by flow cytometry
and the supernatants were clarified and immunoblotted with anti-IL-1b or anti-
His to determine the fraction of cleaved extracellular IL-1b. Alternatively, the
known caspase-1 inhibitor PI-9 was added into the medium of a standard
signal II assay, before signal-II addition, at concentrations that were sufficient
to block recombinant caspase-1-mediated proteolysis of recombinant pro-IL-
1b. IL-1b proteolysis was then determined by immunoblotting.
Staining Extracellular IL-1b
Coverslips were coated overnight with IL-1b capture antibody (5 mg/ml) and
then THP-1 cells, treated with PMA (250 nM), were plated overnight. Cells
were then incubated in RPMI for 2 hr to encourage attachment to the slides
and then treated with PMA (250 nM) and Nigericin (2 mM) or ouabain
(1.25 mM) for 1–5 hr. FITC-conjugated IL-1b secondary antibody was then
added and incubated for 15 min, followed by a gentle PBS wash. Mitotracker
CMX-ROS (200 mM) was used to stain live cells, and cells were washed with
PBS and then fixed and washed again with PBS, including 20 mM Hoechst
for 10 min. Cells were mounted with Slow Fade (Molecular Probes) and
observed on a laser scanning microscope (Olympus FV1000) using a 488-
nm argon laser (green fluorescence) and a 405-nm LD laser (Hoechst).
Confocal images were acquired with Fluoview 1000 V.1 application software,
and images were processed with Indesign (Adobe).
Inhibition of IL-1b Release by KCL or Glyburide
THP-1 cells were primed with LPS (1 mg/ml). Four hours later, cells were either
left untreated or treated with KCL or glyburide (2.5–40mM) for 1 hr, followed by
treatment with signal II agents. Cells and supernatants were then processed as
described above.SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures and can be found with this
article online at http://dx.doi.org/10.1016/j.celrep.2015.05.003.
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